Carl Zeiss Meditec Remains Strong
Growth in all strategic business units and reporting regions
Medical technology company Carl Zeiss Meditec successfully continued on its growth course in the third quarter and achieved a significant increase in revenue compared with the same period of the previous year.
"I am particular pleased that this substantial growth in revenue has also had a positive effect on earnings," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. The EBIT margin increased from 12.2 percent in the same period of the previous year to 13.6 percent. "This takes us another step closer to achieving our objective of increasing our margin to 15 percent by around 2015," continues Dr. Monz.
Carl Zeiss Meditec has a broad business portfolio, ranging from ophthalmology, through microsurgery, to new applications in radiotherapy. "All strategic business units and reporting regions are contributing to our growth. This shows that our company is in a stable position," says Dr. Ludwin Monz.
Key figures at a glance
In the first 9 months of the current financial year Carl Zeiss Meditec generated consolidated revenue of 555.5 million euros (previous year: 490.8 million euros). This represents an increase of 13.2 percent over the previous year. Growth came from all strategic business units (SBUs). Both the overall positive trend in the market during the reporting period and the further improvement in the company's position as a result of innovative new products contributed to this development. The Microsurgery SBU grew by 20.8 percent compared with the previous year. The significantly higher sales of the radiotherapy device INTRABEAM contributed to this. While the Ophthalmic Systems SBU grew by 8.3 percent, the Surgical Ophthalmology SBU contributed to overall earnings with growth of 7.7 percent.
Revenue growth comes from all reporting regions of Carl Zeiss Meditec. The "Asia/Pacific" region achieved the greatest growth in revenue of 174.2 million euros (23.9 percent). As in the previous quarters, China, India and Southeast Asia showed the most significant growth. The Americas region also achieved double-digit growth of 11.6 percent, to 188.5 million euros. This region continues to be dominated by the USA, although development in Central and South America is also encouraging. The EMEA region is the strongest market in terms of revenue generation, growing by 6.3 percent through the sale of products and solutions to a value of 192.8 million euros.
Earnings before interest and taxes (EBIT) increased to 75.7 million euros (previous year: 60 million euros). The EBIT margin increased from 12.2 percent to 13.6 percent.
"We shall remain on our present course," says Dr. Ludwin Monz. Our stable strategic presence in businesses and regions makes me optimistic about the longer-term development of our company. Particularly in light of the current imponderables concerning the global economy, I consider Carl Zeiss Meditec to be well equipped," said Dr. Monz.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
